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Abstract
Background: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are
effective in 50 % to 70 % of patients with CHC. Several new treatments including Harvoni, Olysio + Sovaldi, Viekira
Pak, Sofosbuvir-based regimens characterized with potent inhibitors have been approved by the Food and Drug
Administration (FDA) providing more options for CHC patients. Trials have shown that the new treatments
increased the rate to 80 % to 95 %, though with a substantial increase in cost. In particular, current market pricing
of a 12-week course of sofosbuvir is approximately US$84,000. We determine the cost-effectiveness of new
treatments in comparison with the standard care of treatments.
Methods: A Markov simulation model of CHC disease progression is used to evaluate the cost-effectiveness of
different treatment strategies based on genotype. The model calculates the expected lifetime medical costs and
quality adjusted life years (QALYs) of hypothetical cohorts of identical patients receiving certain treatments. For
genotype 1, we compare: (1) peginterferon + ribavirin + telaprevir for 12 weeks, followed by 12 or 24 weeks
treatment of peginterferon + ribavirin dependent on HCV RNA level at week 12; (2) Harvoni treatment, 12 weeks; (3)
Olysio + Sovaldi, 12 weeks for patients without cirrhosis, 24 weeks for patients with cirrhosis; (4) Viekira Pak +
ribavirin, 12 weeks for patients without cirrhosis, 24 weeks for patients with cirrhosis; (5) sofosbuvir + peginterferon
+ ribavirin, 12 weeks for patients with or without cirrhosis. For genotypes 2 and 3, treatment strategies include: (1)
peginterferon + ribavirin, 24 weeks for treatment-naïve patients; (2) sofosbuvir + ribavirin, 12 weeks for patients with
genotype 2, 24 weeks for genotype 3; (3) peginterferon + ribavirin as initial treatment, 24 weeks for patients with
genotype 2/3, follow-up treatment with sofosbuvir + ribavirin for 12/16 weeks are performed on non-responders
and relapsers.
Results: Viekira Pak is cost-effective for genotype 1 patients without cirrhosis, whereas Harvoni is cost-effective for
genotype 1 patients with cirrhosis. Sofosbuvir-based treatments for genotype 1 in general are not cost-effective due
to its substantial high costs. Two-phase treatments with 12-week and 16-week follow-ups are cost-effective for
genotype 3 patients and for genotype 2 patients with cirrhosis. The results were shown to be robust over a broad
range of parameter values through sensitivity analysis.
Conclusions: For genotype 1, sofosbuvir-based treatments are not cost-effective compared to Viekira Pak and Harvoni,
although a 30 % reduction in sofosbuvir price would change this result. Sofosbuvir + ribavirin are cost-effective as
second-phase treatments following peginterferon + ribavirin initial treatment for genotypes 2 and 3. However, there is
limited data on sofosbuvir-involved treatment, and the results obtained in this study must be interpreted within the
model assumptions.
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Background
Chronic hepatitis C (CHC) is the leading cause of
chronic liver disease and the primary reason for liver
transplantation [1, 2]. Approximately 170 million people
worldwide are infected with the hepatitis C virus (HCV),
including 4 million people in the US [3, 4]. CHC can go
undetected for years, and once the symptoms do appear,
liver damage has begun [5]. Approximately 42 % of CHC
patients will develop cirrhosis in their lifetime [6]. Fur-
ther, 23 % of these patients, if untreated, will eventually
develop hepatocellular carcinoma, the primary cause of
liver disease induced mortality [7]. In advanced stages of
cirrhosis, liver transplantation is typically the only treat-
ment option [8].
In the last few years, the standard of care for untreated
CHC patients has changed from dual therapy with
peginterfeon and ribavirin to triple treatment with
peginterferon, ribavirin plus protease inhibitors (PI) such
as telaprevir or boceprevir [9]. Although fairly effective
compared to the older dual therapy, this triple therapy
does not achieve more than a 75 % sustained virologic
response (SVR) [10], which is defined as HCV RNA less
than lower limit of quantification (LLOQ) at 12 weeks
after the end of treatment. Once SVR is achieved, re-
lapse is very unlikely. However, injected interferon can
lead to severe side effects such as fatigue, depression,
and emotional liability [2].
In December 2013, sofosbuvir (brand name Sovaldi) as
a new component of interferon-free oral regimen was
approved by the U.S. Food and Drug Administration
(FDA) for treating CHC. The drug eliminates the need
for some patients to take interferon, specifically patients
with genotypes 2 and 3 [11]. These patients can use
sofosbuvir alone with ribavirin, whereas patients with
genotype 1 are recommended to take sofosbuvir in com-
bination with peginterferon and ribavirin [11]. More re-
cently, there have appeared a number of potent inhibitors
that were approved as an all-oral regimen to treat geno-
type 1 (Table 1). In October 2014, the combination of
ledpasvir-sofosbuvir (Harvoni) was approved by the FDA
for the treatment of genotype 1 CHC patients with or
without cirrhosis [12]. One month later, the use of
simeprevir (brand name Olysio) in combination with
sofosbuvir was also approved for genotype 1 patients [13].
A month later, Viekira Pak comprised of four medications
(ombitasvir, paritaprevir, ritonavir and dasabuvir) was ap-
proved for genotype 1 patients as well [14]. These new
treatments are characterized by significant increases in
SVR [15]. The traditional regimen of peginterferon plus ri-
bavirin is effective in 50 % to 70 % of patients with CHC.
These new regimens as combinations of inhibitors in-
creased the effective rate to 80 % to 95 % [12–14, 16–18].
However, as a popular component of new treatments,
current market pricing of a 12-week course of sofosbuvir
alone costs roughly $84,000 [19, 20]. We determine the
cost-effectiveness of sofosbuvir-involved treatments in
comparison with interferon-based treatments. To date,
such analysis has not been reported, except for a recent
study that found sofosbuvir-based treatments to be cost-
effective for incarcerated persons [21].
Methods
We apply a Markov simulation model of CHC disease
progression to evaluate the cost-effectiveness of different
treatment strategies for CHC. The model calculates the
expected lifetime medical costs and quality adjusted life
years (QALYs) of hypothetical cohorts of identical pa-
tients receiving certain treatments. Treatments are com-
pared based on the ratio of the additional cost of the
more costly treatment divided by the additional effect-
iveness of the treatment. Reference patient cohorts are
defined according to the average characteristics, gender
and age, obtained from the trials used in this study (52-
years old, 64 % male, treatment-naïve who have CHC
with or without cirrhosis).
At the beginning of a period, each hypothetical patient
receives a designated treatment. If the patient shows de-
tectable HCV RNA by a PCR test throughout the ther-
apy, the patient is classified as a non-responder. If a
patient is HCV negative during therapy and also nega-
tive in the test 12 weeks after treatment, we assume SVR
is achieved. Otherwise, a relapse occurs. Whether a non-
responder or relapser will receive follow-up treatment
depends on the specific treatment plan. After receiving
treatment, each patient enters a Markov process based
on the viral response result. Subsequent long-term prog-
nosis of each treatment group is then estimated using
simulation, and the cohort is tracked as a patient moves
through different health states until death. Transitions
are made annually based on natural disease progres-
sion and each year patients may remain in the same
state or transit to another state. In accordance with
the literature, [6, 22–25] the costs and benefits are
discounted at an annual rate of 3 %. All costs are ad-
justed to 2014 U.S. dollars.
Table 1 FDA recommendations [19]
Genotype Treatment Duration (weeks)
1 Harvoni 12
Olysio + Sovaldi with or without
Ribavirin
12 (no cirrhosis), 24
(cirrhosis)
Viekira Pak + Ribavirin 12 (no cirrhosis), 24
(cirrhosis)
Sovaldi + Peginterferon + Ribavirin 12
2 Sovaldi + Ribavirin 12
3 Sovaldi + Ribavirin 24
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Efficacy rates of treatments
Efficacy data associated with sofosbuvir-based new treat-
ments are extracted from five clinical studies [16–18].
These studies include a total of 1724 HCV mono-
infected patients with genotypes 1 to 6 CHC. It should
be noted that these five trials targeted different patient
cohorts. The primary ending point was SVR at 12 weeks
after the end of treatment. In the NEUTRINO study, [17]
a 12-week treatment was evaluated with Sovaldi + pegin-
terferon-alpha + ribavirin in treatment-naïve subjects with
genotype 1,4,5,6. In the study, 90 % of patients had a SVR
with 89 % for patients with genotype 1. The SVR rate was
92 % among patients without cirrhosis and 80 % among
those with cirrhosis. Aiming at treatment-naïve subjects
with genotypes 2 and 3, the FISSON study compared 12-
week treatment with Sovaldi and ribavirin to a 24-week
treatment with peginterferon-alpha plus ribavirin [17].
SVR categorized by genotype and cirrhosis is shown in
Tables 2 and 3. The FUSION study conducted experi-
ments on patients previously treated with interferon with
genotypes 2 or 3 who either relapsed or failed to respond,
and a 12- or 16-week treatment with Sovaldi and ribavirin
was performed [16]. The VALENCE trial showed that for
treatment-naïve genotype 3 patients, Sovaldi plus ribavirin
for 24-week treatment obtained a 93 % SVR with no cir-
rhosis and a 92 % SVR with cirrhosis [18]. For Harvoni
treatment, phase 3 studies (ION-1,ION-2,ION-3) have
consistently shown SVR rates greater than 90 % with a 12-
week course in patients of genotype 1 CHC with or with-
out cirrhosis [12]. According to the COSMOS study, SVR
rates were 95 % for non-cirrhotic patients with 12-week
treatment of Olysio + Sovaldi and 100 % for cirrhotic pa-
tients with 24-week treatment [13]. Viekira Pak + ribavirin
regimens were characterized with 95 % SVR for non-
cirrhotic patients with 12-week treatment (SAPPHIRE-I
study) and 95 % for cirrhotic patients with 24-week treat-
ment (TURQOUISE study) [14]. In all of these trials,
treatments were not guided by subjects’ HCV RNA levels,
implying that a no response-guided algorithm was used.
As benchmarks, we consider pegylated interferon,
ribavirin plus telaprevir therapy as the standard care for
genotype 1 and pegylated interferon plus ribavirin as the
standard care for genotypes 2 and 3. They are commonly
accepted treatments and acknowledged to be cost-
effective in previous literature. Telaprevir is given with
peginterferon and ribavirin for the first 12 weeks of ther-
apy, followed by an additional 12 or 36 weeks of pegin-
terferon and ribavirin depending on the response during
therapy. If HCV RNA levels are undetectable at week 12
of treatment, an additional 12 weeks of peginterferon
and ribavirin should be received, otherwise an additional
24 weeks of peginterferon and ribavirin are expected. As
sofosbuvir also works for relapsers and non-responders
with genotypes 2 and 3, we design a follow-up treatment
of sofosbuvir plus ribavirin for patients who experience
prior interferon treatment failure. We assume that all
patients who participate in sofosbuvir-involved therapy
either as initial or follow-up treatment complete the
whole course of treatment. Subsequent prognosis of pa-
tients who relapse after the whole treatment is assumed
to be identical to those who never have treatment.
In this study, we discuss treatment strategies based on
genotypes. For genotype 1, the following treatment strat-
egies are compared: (1) peginterferon + ribavirin + telapre-
vir for 12 weeks, followed by an additional 12 or 24 weeks
treatment of peginterferon + ribavirin dependent on HCV
RNA level at week 12; (2) Harvoni treatment, 12 weeks;
(3) Olysio + Sovaldi, 12 weeks for patients without cirrho-
sis, 24 weeks for patients with cirrhosis; (4) Viekira Pak +
ribavirin, 12 weeks for patients without cirrhosis, 24 weeks
Table 2 Response rates for patients without cirrhosis
Genotype Treatment Duration (weeks) SVR (%) Trials
1 Telaprevir + Peginterferon-alpha + Ribavirin 12 + 12 or 12 + 36 75 ADVANCE
Harvoni 12 98 ION
Olysio + Sovaldi 12 95 COSMOS
Viekira Pak + Ribavirin 12 96 SAPPHIRE
Sofosbuvir + Peginterferon + Ribavirin 12 92 NEUTRINO
2 Peginterferon + Ribavirin (Treatment-naïve) 24 81 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 12 97 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 90 FUSION
16 92 FUSION
3 Peginterferon + Ribavirin (Treatment-naïve) 24 81 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 24 93 VALENCE
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 37 FUSION
16 63 FUSION
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for patients with cirrhosis; (5) sofosbuvir + peginterferon
+ ribavirin, 12 weeks for patients with or without cirrhosis.
For genotypes 2 and 3, treatment strategies include: (1)
peginterferon + ribavirin, 24 weeks for treatment-naïve pa-
tients; (2) sofosbuvir + ribavirin, 12 weeks for patients with
genotype 2, 24 weeks for genotype 3; (3) peginterferon +
ribavirin as initial treatment, 24 weeks for patients with
genotype 2/3, follow-up treatment with sofosbuvir + riba-
virin for 12/16 weeks are performed on non-responders
and relapsers. We do not explicitly consider the case of
patients where interferon containing therapy is not an op-
tion because of contraindications or because interferon
based therapy has failed.
The Markov simulation model includes the following
CHC associated health states: CHC, treatment induced
cure, and liver disease induced death [5, 6]. In addition,
patients at each health state are subject to the same age-
dependent other cause induced death rate. Transition
occurs annually and depends on health state-specific
transition probabilities. Due to a lack of well-designed
studies of patients with CHC, transition probabilities are
estimated from the most widely quoted published data.
Age-dependent death rates are obtained from the 2008
United States life table [26].
Health-state related quality adjusted life years
Quality of life specific to different health states are
adjusted on an annual scale from 1 (perfect health) to 0
(death). Estimates of utilities were based on actual pa-
tients’ utilities using the health utility index [27]. To esti-
mate treatment-specific QALYs, the time spent in each
health state was multiplied by each utility value and then
summed over the life expectancy. As interferon based
therapy has significant side effects, a 9 % reduction in
utility is assumed for interferon-based therapy [22, 25].
Since most side effects are significantly more common
in interferon containing regimens as compared to
interferon-free ones, we assume that adding sofosbuvir
in a regimen does not change the QALY values.
Medical costs
Medical costs are summarized in Tables 4 and 5. Drug
costs are estimated using approximate 2014 average
wholesale acquisition prices [12–14, 20]. Other therapy
related costs including screening, diagnostic and labora-
tory testing, drugs, monitoring costs during therapy and
follow-up periods are estimated from the literature. An-
nual costs associated with each health state have been
previously discussed and are inflated to 2014 US dollars
using the medical care component of the Consumer
Price Index [28].
Sensitivity analysis
In order to evaluate the robustness of the model, sensi-
tivity analysis is performed for all parameters. Specific-
ally, a 95 % confidence interval is used for each entry of
utility weights and natural history transition probabil-
ities. Costs are halved and doubled. In terms of response
rate, the model is reanalyzed for ±10 % change of the
value for each efficacy. A variable is considered to be po-
tentially influential if it leads to the change of effective-
ness for a treatment. In addition to one-way sensitivity
analyses for all variables, we conduct probabilistic sensi-
tivity analyses. It is based on Monte Carlo simulation
with 1000 runs, where parameters are varied randomly
according to associated distributions. This approach
examines the effect of joint uncertainty in the model’s
variables. We assume that transition probabilities and
utilities follow a uniform distribution with ranges speci-
fied in Tables 6 and 7. Treatment efficacies follow a Beta
Table 3 Response rates for patients with cirrhosis
Genotype Treatment Duration (weeks) SVR (%) Trials
1 Telaprevir + Peginterferon-alpha + Ribavirin 12 + 12 or 12 + 36 75 ADVANCE
Harvoni 12 98 ION
Olysio + Sovaldi 24 100 COSMOS
Viekira Pak + Ribavirin 24 95 TURQOUISE
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 80 NEUTRINO
2 Peginterferon + Ribavirin (Treatment-naïve) 24 62 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 12 83 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 60 FUSION
16 78 FUSION
3 Peginterferon + Ribavirin (Treatment-naïve) 24 30 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 24 92 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 19 FUSION
16 61 FUSION
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distribution and costs follow a Gamma distribution, all




Treatments aimed at the same group of patients (geno-
type, existence of cirrhosis) are compared. We consider
results categorized by whether cirrhosis exists. The re-
sults for patients without cirrhosis are shown in Table 8,
and the results for patients with cirrhosis are shown in
Table 9. Note that the treatments are sorted according
to cost in ascending order. In both tables, the incremen-
tal cost-effectiveness ratio (ICER) is calculated as the
additional cost divided by additional effectiveness be-
tween each treatment and the benchmark treatment.
Specifically, all treatments are first compared to the
standard of care treatment (e.g., standard of care treat-
ment for genotype 1 is Telaprevir + Peginterferon + Riba-
virin), and then compared to the adjacent efficient
treatment. For example, in Table 8 for genotype 2, the
Adjacent ICER between two-phase treatment with 24 + 12
versus Peginterferon + Riavirin is 4233. The Adjacent
ICER between two-phase treatment with 24 + 16 versus
two-phase treatment with 24 + 12 is 44,458. The Adjacent
ICER between Sofobuvir + Ribavirin versus two-phase
treatment with 24 + 16 is 1,805,952.
For genotype 1 patients without cirrhosis, compared
to the acknowledged efficient benchmark treatment
(peginterferon + ribavirin + telaprevir), all new treat-
ments are cost-effective with ICER less than the
threshold of $50,000/QALY. In particular, treatments
Harvoni and Viekira Pak both achieve higher QALYs
with reduced costs, which makes the benchmark
treatment no longer efficient, whereas treatments oly-
sio + sovaldi and sofosbuvir + peginterferon + ribavirin
both achieve higher QALYs but with increased costs
compared to benchmark treatment. However, if com-
pared to Viekira + Pak, Harvoni, olysio + sovaldi and
sofosbuvir + peginterferon + ribavirin are no longer ef-
ficient characterized with higher costs and lower
QALYs. Thus, we conclude that all four new regimens
are alternatives of the current standard care of treat-
ment (peginterferon + ribavirin + telaprevir), but Vie-
kira Pak is the most cost-effective for genotype 1
patients without cirrhosis, whereas the other three
sofosbuvir-based treatments are featured with higher
costs and lower QALYs. For genotype 2 treatments,
compared to standard care of treatment (peginter-
feron + ribavirin), all three sofosbuvir-based treatments
are cost-effective. However, the comparative ICER of
two-phase treatment with a 16-week follow-up versus
12-week single treatment of sofosbuvir + ribavirin is
$1,805,952/QALY, which is far beyond the threshold.
Thus, for genotype 2 the two-phase treatments with
peginterferon + ribavirin as initial and 12 and 16 weeks
of sofosbuvir as follow-up are cost-effective, whereas
single treatment with sofosbuvir + ribavirin is not. For
genotype 3, similarly, the two-phase sofosbuvir-based
treatments are cost-effective compared to the stand-
ard care of treatment; note that ICERs between adja-
cent treatments are also below the threshold. The 24-
week single treatment with sofosbuvir + ribavirin is
not cost-effective compared to standard care of treat-
ment with an ICER of $88,833/QALY. Further, it is
not cost-effective compared to two-phase treatment
with a 16-week follow-up with an ICER of $374,594/
QALY. Overall, single-phase treatment with sofosbuvir
for both genotype 2 and 3 patients dominates two-
phase treatments using peginterferon + ribavirin regi-
men as initial and sofosbuvir-based new treatment as
follow-up. The reason is attributable to the fact that the
traditional regimen (peginterferon + ribavirin) has a rela-
tively high SVR for genotypes 2 and 3, and the new treat-
ment's additional SVR increase does not justify its much
higher cost.
When patients with cirrhosis are considered, for
genotype 1 all new treatments are efficient compared
to the standard care of treatment, whereas adjacent
ICERs show that sofosbuvir + peginterferon + ribavrin
and Viekira Pak are both inefficient compared to Har-
voni with higher costs and lower QALYs. Although
olysio + sovaldi has higher cost as well as higher QALYs
compared to Harvoni, the ICER is $1,305,213/QALY,
which is far beyond the threshold and hence not efficient.
Therefore, for genotype 2 patients with cirrhosis, Harvoni
Table 4 Annual costs of care
Annual costs of care
(2014 US$)
Reference
Chronic Hepatitis C $572.69 [25]
Compensated Cirrhosis $762.99 [25]
Decompensated Cirrhosis $39,675.48 [25]
HCC $25,862.67 [25]
Liver Transplant (1st year) $483,057.01 [25]
Liver Transplant (successive year) $46,515.46 [25]
Table 5 Weekly cost of treatments
Treatment Cost per week (2014 US$)
Harvoni $7,875.00
Olysio + Sovaldi $12,500.00
Viekira Pak + Ribavirin $7,000.00
Ribavirin $250
Peginterferon + Ribavirin $750
Sofosbuvir $7,000
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is the most cost-effective treatment. For genotype 2, both
two-phase treatments with 12-week and 16-week follow-
ups are cost-effective, whereas 12-week single treatment
with sofosbuvir + ribavirin is not cost-effective. For geno-
type 3 treatments, a 24-week single treatment with sofos-
buvir + ribavirin is cost-effective, as well as the two-phase
treatment with a 16-week follow-up.
Sensitivity analysis
One-way sensitivity analyses are performed on prices,
transition probabilities, SVR rates, utility weights and
costs of care. Only when the sofosbuvir price is reduced
by at least 30 %, olysio + sovaldi and sofosbuvir + peginter-
feron + ribavirin can achieve cost-effectiveness compared
to Harvoni or Viekira Pak for genotype 1 patients. How-
ever, even when the sofosbuvir price is halved, using
sofosbuvir as initial treatment is still not cost-effective
compared to two-phase treatments that use sofosbuvir as
a follow-up treatment for genotypes 2 and 3. Further,
increasing SVR for sofosbuvir-based treatments by 10 %
does make them cost-effective compared to Harvoni and
Viekira Pak for genotype 1 patients, and reducing SVR for
Harvoni and Viekira Pak by 10 % also makes sofosbuvir-
based treatments cost-effective.
Changing SVR rates of sofosbuvir-based treatments for
genotypes 2 and 3 does not change the effectiveness of the
treatments. Two-phase treatments of 24 + 12 weeks are al-
ways cost-effective for both genotypes 2 and 3, compared
to which, a change in the values of cost of care or utility
weights can push 24 + 16 weeks treatments’ ICER beyond
or below $50,000/QALY when benchmarked with the base
case. However, it does not change the conclusion that sin-
gle phase treatment of sofosbuvir + ribavirin is not cost-
effective for both genotypes 2 and 3. Thus, for genotype 1
patients, a reduction in sofosbuvir price can improve the
cost-effectiveness of sofosbuvir-based treatments com-
pared to the alternatives of Harvoni and Viekira Pak. For
genotypes 2 and 3, however, sofosbuvir-based new treat-
ments serve better as follow-up treatments rather than
initial treatments.
Probabilistic analysis results are shown via the cost-
effectiveness acceptability curves (Fig. 1), which are
interpreted as the probability that the data are con-
sistent within a true cost-effectiveness ratio falling
below that value between two treatments. The figure
that the ICER of olysio + sovaldi versus Harvoni falls
either below 0 or above $50,000/QALY with approxi-
mate probability 0.95, implying that compared to Har-
voni, olysio + sovaldi either achieves lower QALYs
with higher costs or achieves higher QALYs with
higher cost but with ICER exceeding the threshold
$50,000/QALY. Thus, with 95 % confidence we con-
clude that olysio + sovaldi is not cost-effective. For
Viekira Pak and sofosbuvir + peginterferon + ribavirin,
Table 6 Annual transitions (stated as percentages)
Transition Baseline Range Reference
Chronic Hepatitis C
to Compensated Cirrhosis 7.30 % 1.0 %-23.2 % [6, 25]
Compensated Cirrhosis
to Decompensated Cirrhosis 3.90 % 2.0 %-8.3 % [22, 25, 29]
to HCC 3.70 % 1.0 %-4.4 % [25, 30, 31]
Decompensated Cirrhosis
to HCC 3.70 % 1.0 %-4.4 % [25, 29, 30]
to Liver Transplant 3 % 1.0 %-6.2 % [22, 25]
to Liver-induced Death 12.90 % 6.5 %-19.3 % [15, 22, 24, 29]
HCC
to Liver Transplant 3 % 1.0-6.2 % [22, 25]
to Liver-induced Death 42.70 % 33 %-86 % [25, 29]
Liver Transplant
to Liver-induced Death, first year 13.70 % 6 %-42 % [25, 32]
to Liver-induced Death, successive year 5.20 % 2.4 %-11 % [25, 32]
Table 7 Health-state specific QALYs
QALYs Baseline Range Reference
Uninfected 1 1 [27]
Chronic Hepatitis C 0.82 0.6-0.9 [27]
Compensated Cirrhosis 0.78 0.5-0.9 [27]
Decompensated Cirrhosis 0.65 0.3-0.88 [27]
HCC 0.25 0.1-0.5 [27]
Liver Transplant (1st year) 0.5 0.11-0.7 [27]
Liver Transplant (successive year) 0.7 0.24-0.87 [27]
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compared to Harvoni, they both have roughly a 0.50
probability of being effective according to figure. For
both genotypes 2 and 3, the ICER of two-phase treat-
ment with peginterferon + ribavirin as initial and 12-
week sofosbuvir as follow-up versus the standard of
treatment is below $10,000/QALY with 0.95 probabil-
ity according to the figure, whereas two-phase treat-
ment with peginterferon + ribavirin as initial, a 16-
week sofosbuvir as follow-up and single treatment
with sofosbuvir + ribavirin both have equal probability
of being effective and not effective for genotypes 2
and 3.
Discussion
Our analyses show that Viekira Pak is cost-effective for
genotype 1 patients without cirrhosis, while Harvoni is
cost-effective for genotype 1 patients with cirrhosis.
Sofosbuvir-based treatments for genotype 1, in general,
are not cost-effective due to its substantial high costs. The
price of Sofosbuvir would need to be reduced by at least
30 % in order for olysio + sovaldi and sofosbuvir + pegin-
terferon + ribavirin to achieve cost-effectiveness. For geno-
types 2 and 3, sofosbuvir + ribavirin as initial treatment
comes with a large increase in cost and a small increase
in effectiveness. It is not recommended as an initial











1 Viekira Pak + Ribavirin 12 97,380 19.9659 dominant
Harvoni 12 106,830 19.9618 dominant dominated
Telaprevir + Peginterferon + Ribavirin for first 12 weeks,
followed by additional 12 or 36 weeks of Peginterferon
+ Ribavirin
12 + 12 or
36
108,820 18.3364 benchmark dominated
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 111,790 19.568 2,412 dominated
Olysio + Sovaldi 12 165,220 19.9356 35,268 dominated
2 Peginterferon + Ribavirin (Treatment-naïve) 24 45,560 18.7853 benchmark
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir
+ Ribavirin for non-responders and relapsers.
24 + 12 50,340 19.9145 4,233 4,233
24 + 16 54,030 19.9975 6,987 44,457
Sofosbuvir + Ribavirin (Treatment-naïve) 12 99,540 20.0227 43,624 1,805,952
3 Peginterferon + Ribavirin (Treatment-naïve) 24 52,810 18.2828 benchmark
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir
+ Ribavirin for non-responders and relapsers.
24 + 12 69,390 18.9351 25,418 25,418
24 + 16 70,220 19.4892 14,431 1,498
Sofosbuvir + Ribavirin (Treatment-naïve) 24 187,880 19.8033 88,833 374,594











1 Harvoni 12 108,000 19.9787 dominant
Telaprevir + Peginterferon + Ribavirin for first 12 weeks,
followed by additional 12 or 36 weeks of Peginterferon
+ Ribavirin
12 + 12 or
36
122,420 17.2075 benchmark dominated
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 130,750 17.8475 13,016 dominated
Viekira Pak + Ribavirin 24 186,820 19.7603 25,227 dominated
Olysio + Sovaldi 24 313,310 20.136 65,184 1,305,213
2 Peginterferon + Ribavirin (Treatment-naïve) 24 81,070 15.874 benchmark
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir
+ Ribavirin for non-responders and relapsers.
24 + 12 81,920 18.4461 330 330
24 + 16 82,240 19.3293 339 362
Sofosbuvir + Ribavirin (Treatment-naïve) 12 119,940 18.4217 15,257 dominated
3 Peginterferon + Ribavirin (Treatment-naïve) 24 121,170 12.2543 benchmark
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir
+ Ribavirin for non-responders and relapsers.
24 + 16 147,520 17.1869 5,342 5,342
24 + 12 162,490 13.8563 25,793 dominated
Sofosbuvir + Ribavirin (Treatment-naïve) 24 191,280 19.3615 9,865 20,123
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treatment for patients with genotypes 2 and 3, with the
exception of genotype 3 with cirrhosis, in which case, a
24-week sofosbuvir + ribavirin treatment is cost-effective
as it leads to much higher SVR compared to alternative
treatments. As a second-phase treatment for genotypes 2
and 3, sofosbuvir + ribavirin is cost-effective following
peginterferon + ribavirin as initial treatment.
To assure the robustness of our results, we per-
formed sensitivity analyses over wide ranges for all
model parameters, and the results did not signifi-
cantly impact our final conclusions. However, it is im-
portant to note that the results obtained in this study
should be interpreted within the model assumptions,
and there are several limitations. First, model parame-
ters were obtained from the literature and there is
limited data on sofosbuvir-involved treatment. Further,
the SVR rates used from the five trials targeted differ-
ent patient cohorts. Bias in these past studies could
impact the results presented here. In addition, the
Markov model used in the analysis is a simplified
representation of disease progression based on aggre-
gate population transitions. Although we believe that
we have captured the primary stages, a higher fidelity
model could lead to different conclusions. Finally, the
population data is specific to the United States, and
so the results might not be directly applicable to
other countries.
Conclusions
We analyzed the cost-effectiveness of sofosbuvir-based
new treatments for genotypes 1, 2 and 3 in the US. Data
regarding the natural history of hepatitis C, utility
weights, and various costs and transition probabilities
were obtained from the literature, and sustained viro-
logic response data associated with new treatments were
extracted from clinical studies. Treatment strategies
compared in this study were designed based on the data
available while complying with drug dosage and admin-
istrative recommendations.
We found that for genotype 1 patients, sofosbuvir-
based treatments are not cost-effective compared to
Viekira Pak and Harvoni. If the price of sofosbuvir were
reduced by at least 30 %, then this would change
this result. In addition, Sofosbuvir + ribavirin are cost-
effective as second-phase treatments following peginter-
feron + ribavirin initial treatment for genotypes 2 and 3.
However, the data for sofosbuvir-involved treatment is
limited. Therefore, the results obtained in this study
must be interpreted within the model assumptions.
Fig. 1 Cost-effectiveness Acceptability Curves between Treatments. Olysio + Sovaldi versus Harvoni for Genotype 1 (Subfigure 1); Viekira Pak versus
Harvoni for Genotype 1 (Subfigure 2); Sofosbuvir + Peginterferon + Ribavirin versus Harvoni for Genotype 1 (Subfigure 3); Two-phase of 24 + 12
versus Peginterferon + Ribavirin for Genotype 2 (Subfigure 4); Two-phase of 24 + 16 versus Two-phase of 24 + 12 for Genotype 2 (Subfigure 5);
Sofosbuvir + Ribavirin versus Two-phase of 24 + 16 for Genotype 2 (Subfigure 6); Two-phase of 24 + 12 versus Peginterferon + Ribavirin for
Genotype 3 (Subfigure 7); Two-phase of 24 + 16 versus Two-phase of 24 + 12 for Genotype 3 (Subfigure 8); Sofosbuvir + Ribavirin versus Two-phase
of 24 + 16 for Genotype 3 (Subfigure 9)
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